MARKETS.

The one thing about blockbusters? They often cost more than they should. We intend to supply plant-based biosimilar drug product to commercialization entities at an anticipated one-tenth the cost per gram for the upstream process in which we excel. 

​

Let's get specific: Hyaluronidase is an increasingly sourced drug product used by CDMOs and biosimilar corporations, to convert intravenous (IV) drugs into more patient-friendly subcutaneous (under-the-skin) injections. This conversion allows pharmaceutical companies to secure new patents on the subcutaneous formulation, effectively expanding the market exclusivity of their blockbuster therapies beyond the original IV drug patent expiration. Phylloceuticals can provide a plant-made version of hyaluronidase, securing a domestic supply that is clean, safe and available, for biosimilar manufacturers.

Phylloceuticals can fill gaps in current drug development inside the massive biopharmaceutical R&D maze. We see AI data scientists, transforming early discovery, and generating millions of sequences, which are hard to handle inside even the largest, most robust early discovery labs. Some of the sequences appear too difficult to make, and could get eliminated too early. 

​

This is a challenge Phylloceuticals can address. Our plant-based platform can screen early discovery candidates so rapidly that scientists will have data back in hand in weeks. This allows a wider number of sequences to be screened, on budget, and provide scientist the data for a go/no-go decision much faster than using mammalian cell platforms. 

One of the least understood and least explored paradigms in biopharmaceutical manufacturing is a lack of "switchability". If a facility is set up to make one biologic, despite engineering efforts to create nimble, multi-product facilities, the reality is often a single product, non-nimble facility that makes one drug. When you are growing plants hydroponically, and the plants are your bioreactors, switching to a new product is a matter of growing more plants (did we say that our plant is the fastest growing on the planet?)

​

Even a brand new facility can be up and running in weeks and making product. The possibilities for national defense modular facilities and fast-response pandemic switchability for new variants is a key advantage of Phylloceuticals' plant-platform. 

Scalability is a unique selling point here at Phylloceuticals. We can produce massive quantities or micro-scale operations affordably, which makes us unique. This opens opportunities for point-of-care delivery, solving issues related to drug shortages and unpredictable demand in healthcare systems. It also results in equitable distribution of therapeutics. Our system provides a valuable service to healthcare systems for distributed manufacturing. This sets us apart from other big players. When therapeutic healthcare systems struggle to predict demand for key medicine needs, Phylloceuticals can help. 

This is a particular sweet spot for Phylloceuticals. There have always been drugs ideated by brilliant R&D scientists that current production platforms cannot make. 

​

AI is increasing the number of candidates and sequences that can be considered at a pace that humans have trouble meeting. But plants can handle challenges like screening multiple candidates and handling difficult folding and complex sugar profiles. Bring us your novel candidate, your bispecific, your hard-to-make therapeutic protein and let us show you some data. 

There is increasing demand from national and regional healthcare systems to secure their own supplies of needed medicine. The Phylloceuticals approach is easily installed, then portable, with switchability for changing to other, more critically needed therapeutics. This is the future - local production, made easier.